Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$18.07 - $25.6 $2.86 Million - $4.05 Million
158,185 New
158,185 $3.19 Million
Q3 2022

Nov 14, 2022

BUY
$20.23 - $31.73 $696,498 - $1.09 Million
34,429 Added 29.08%
152,808 $3.31 Million
Q2 2022

Aug 15, 2022

SELL
$17.91 - $52.25 $451,761 - $1.32 Million
-25,224 Reduced 17.57%
118,379 $3.33 Million
Q1 2022

May 11, 2022

SELL
$41.58 - $80.89 $1,039 - $2,022
-25 Reduced 0.02%
143,603 $6.63 Million
Q4 2021

Feb 11, 2022

BUY
$66.92 - $84.79 $334,666 - $424,034
5,001 Added 3.61%
143,628 $12.1 Million
Q3 2021

Nov 12, 2021

BUY
$46.83 - $73.5 $2.05 Million - $3.22 Million
43,779 Added 46.16%
138,627 $9.24 Million
Q2 2021

Aug 11, 2021

BUY
$37.41 - $62.25 $188,808 - $314,175
5,047 Added 5.62%
94,848 $5.05 Million
Q1 2021

May 13, 2021

SELL
$35.69 - $52.72 $243,441 - $359,603
-6,821 Reduced 7.06%
89,801 $3.9 Million
Q4 2020

Feb 09, 2021

BUY
$31.71 - $57.97 $2.01 Million - $3.67 Million
63,303 Added 189.99%
96,622 $5.02 Million
Q3 2020

Nov 12, 2020

BUY
$27.03 - $47.97 $58,303 - $103,471
2,157 Added 6.92%
33,319 $1.09 Million
Q2 2020

Aug 12, 2020

BUY
$23.2 - $54.8 $722,958 - $1.71 Million
31,162 New
31,162 $1.5 Million

Others Institutions Holding ZNTL

About Zentalis Pharmaceuticals, Inc.


  • Ticker ZNTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,983,600
  • Market Cap $166M
  • Description
  • Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...
More about ZNTL
Track This Portfolio

Track Bank Of New York Mellon Corp Portfolio

Follow Bank Of New York Mellon Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.